Recent advances in therapeutic delivery systems of bacteriophage and bacteriophage-encoded endolysins

Therapeutic Delivery

Volumn 8, Issue 7, 2017, Pages 543-556

  Hathaway, Hollie ^a   Milo, Scarlet ^a   Sutton, J Mark ^b   Jenkins, Toby A ^a  

^a University of Bath   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

bacteriophage; complexation; controlled release; delivery system; encapsulation; endolysin; immobilization; stimuli responsive

Indexed keywords

ANTIBIOTIC AGENT; ENDOLYSIN; POLYMER; UNCLASSIFIED DRUG; PROTEINASE;

AEROSOL; BACTERIOPHAGE; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; IMMOBILIZATION; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; REVIEW; BACTERIAL INFECTION; BACTERIUM;

BACTERIA; BACTERIAL INFECTIONS; BACTERIOPHAGES; DRUG DELIVERY SYSTEMS; ENDOPEPTIDASES; HUMANS; PHAGE THERAPY;

EID: 85021143778     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde-2017-0040     Document Type: Review

References (91)

1. Sir Alexander Fleming-Nobel Lecture: Penicillin. www.nobelprize.org/nobel-prizes/medicine/laureates/1945/ fleming-lecture.html
2. Nobrega FL, Costa AR, Kluskens LD, Azeredo J. Revisiting phage therapy: new applications for old resources. Trends in Microbiol.23(4), 185-191 (2015).
3. Twort FW. The discovery of the 'bacteriophage'. The Lancet 205(5303), 845 (1925).
4. Hendrix RW. Bacteriophages: evolution of the majority. Theor. Popul. Biol.61(4), 471-480 (2002).
5. Campbell A. The future of bacteriophage biology. Nat. Rev. Genet. 4(6), 471-477 (2003).
6. Cisek AA, DAbrowska I, Gregorczyk KP, WyZewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr. Microbiol. 74(2), 277-283 (2017).
7. Magnone JP, Marek PJ, Sulakvelidze A, Senecal AG. Additive approach for inactivation of Escherichia coli O157:H7, Salmonella, and Shigella spp. on contaminated fresh fruits and vegetables using bacteriophage cocktail and produce wash. J. Food Prot. 76(8), 1336-1341 (2013).
8. Schmelcher M, Loessner MJ. Application of bacteriophages for detection of foodborne pathogens. Bacteriophage 4(2), e28137 (2014).
9. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virol. J. 9(1), 9 (2012).
10. Weber-Dbrowska B, Joczyk-Matysiak E, aczek M, obocka M, usiak-Szelachowska M, Górski A. Bacteriophage procurement for therapeutic purposes. Front. Microbiol. 7, 1177 (2016).
11. Jassim SAA, Limoges RG. Natural solution to antibiotic resistance: bacteriophages 'the living drugs'. World J. Microbiol. Biotechnol. 30(8), 2153-2170 (2014).
12. Sarhan WA, Azzazy HME. Phage approved in food, why not as a therapeutic Expert Rev. Anti Infect. Ther. 13(1), 91-101 (2015).
13. Kingwell K. Bacteriophage therapies re-enter clinical trials. Nat. Rev. Drug Discov. 14(8), 515-516 (2015).
14. Evaluation of phage therapy for the treatment of escherichia coli and pseudomonas aeruginosa wound infections in burned patients (PHAGOBURN). https://clinicaltrials.gov/ct2/show/NCT02116010
15. Ascending dose study of the safety of AB-SA01 when topically applied to intact skin of healthy adults. https://clinicaltrials.gov/ct2/show/NCT02757755
16. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34(4), 349-357 (2009).
17. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J. Wound Care 18(6), 237-238, 240-243 (2009).
18. Mann NH. The potential of phages to prevent MRSA infections. Res. Microbiol. 159(5), 400-405 (2008).
19. Cooper CJ, Khan Mirzaei M, Nilsson AS. Adapting drug approval pathways for bacteriophage-based therapeutics. Front. Microbiol. 7, 1209 (2016).
20. Ly-Chatain MH. The factors affecting effectiveness of treatment in phages therapy. Front. Microbiol. 5, 51 (2014).
21. Srinivasan S, Alexander JF, Driessen WH et al. Bacteriophage associated silicon particles: design and characterization of a novel theranostic vector with improved payload carrying potential. J. Mater. Chem. B 1(39), doi:10.1039/C1033TB20595A (2013) (Epub ahead of print).
22. Yata T, Lee KY, Dharakul T et al. Hybrid nanomaterial complexes for advanced phage-guided gene delivery. Mol. Ther. Nucleic Acids3, e185 (2014).
23. Saboo S, Tumban E, Peabody J et al. Optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus. Mol. Pharm. 13(5), 1646-1655 (2016).
24. van der Merwe RG, van Helden PD, Warren RM, Sampson SL, Gey van Pittius NC. Phage-based detection of bacterial pathogens. Analyst 139(11), 2617-2626 (2014).
25. Bhattarai SR, Yoo SY, Lee SW, Dean D. Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection. Biomaterials 33(20), 5166-5174 (2012).
26. Hosseinidoust Z, Olsson ALJ, Tufenkji N. Going viral: designing bioactive surfaces with bacteriophage. Colloids Surf. B 124, 2-16 (2014).
27. Yosef I, Manor M, Qimron U. Counteracting selection for antibiotic-resistant bacteria. Bacteriophage 6(1), e1096996 (2016).
28. Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl Acad. Sci. USA 112(23), 7267-7272 (2015).
29. Fairhead H. SASP gene delivery: a novel antibacterial approach. Drug News Perspect. 22(4), 197-203 (2009).
30. Sahly H, Podschun R. Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae. Clin. Diagn. Lab. Immunol. 4(4), 393-399 (1997).
31. Cortes G, Alvarez D, Saus C, Alberti S. Role of lung epithelial cells in defense against Klebsiella pneumoniae pneumonia. Infect. Immun. 70(3), 1075-1080 (2002).
32. Singla S, Harjai K, Katare OP, Chhibber S. Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies. PLoS ONE 11(4), e0153777 (2016).
33. Nieth A, Verseux C, Barnert S, Suss R, Romer W. A first step toward liposome-mediated intracellular bacteriophage therapy. Expert Opin. Drug Deliv. 12(9), 1411-1424 (2015).
34. Lusiak-Szelachowska M, Zaczek M, Weber-Dabrowska B et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27(6), 295-304 (2014).
35. Singla S, Harjai K, Katare OP, Chhibber S. Bacteriophage-loaded nanostructured lipid carrier: improved pharmacokinetics mediates effective resolution of Klebsiella pneumoniae-induced lobar pneumonia. J. Infect. Dis. 212(2), 325-334 (2015).
36. Singla S, Harjai K, Raza K, Wadhwa S, Katare OP, Chhibber S. Phospholipid vesicles encapsulated bacteriophage: a novel approach to enhance phage biodistribution. J. Virol. Methods 236, 68-76 (2016).
37. Balcao VM, Glasser CA, Chaud MV, del Fiol FS, Tubino M, Vila M. Biomimetic aqueous-core lipid nanoballoons integrating a multiple emulsion formulation: a suitable housing system for viable lytic bacteriophages. Colloids Surf. B123, 478-485 (2014).
38. Esteban PP, Alves DR, Enright MC et al. Enhancement of the antimicrobial properties of bacteriophage-k via stabilization using oil-in-water nano-emulsions. Biotechnol. Prog. 30(4), 932-944 (2014).
39. Esteban PP, Jenkins ATA, Arnot TC. Elucidation of the mechanisms of action of Bacteriophage K/nano-emulsion formulations against S. aureus via measurement of particle size and zeta potential. Colloids Surf. B139, 87-94 (2016).
40. Ma YS, Pacan JC, Wang Q et al. Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery. Appl. Environ. Microbiol.74(15), 4799-4805 (2008).
41. Ma YS, Pacan JC, Wang Q, Sabour PM, Huang XQ, Xu YP. Enhanced alginate microspheres as means of oral delivery of bacteriophage for reducing Staphylococcus aureus intestinal carriage. Food Hydrocolloids 26(2), 434-440 (2012).
42. Tang Z, Huang X, Sabour PM, Chambers JR, Wang Q. Preparation and characterization of dry powder bacteriophage K for intestinal delivery through oral administration. LWT-Food Sci. Technol. 60(1), 263-270 (2015).
43. Kim S, Jo A, Ahn J. Application of chitosan-alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions. Int. J. Food Sci. Technol.50(4), 913-918 (2015).
44. Pearson HA, Sahukhal GS, Elasri MO, Urban MW. Phage-bacterium war on polymeric surfaces: can surface-anchored bacteriophages eliminate microbial infections Biomacromolecules 14(5), 1257-1261 (2013).
45. Olsson ALJ, Wargenau A, Tufenkji N. Optimizing bacteriophage surface densities for bacterial capture and sensing in quartz crystal microbalance with dissipation monitoring. ACS Appl. Mater. Interfaces 8(22), 13698-13706 (2016).
46. Tawil N, Sacher E, Mandeville R, Meunier M. Strategies for the immobilization of bacteriophages on gold surfaces monitored by surface plasmon resonance and surface morphology. J. Phys. Chem. C 117(13), 6686-6691 (2013).
47. Wang C, Sauvageau D, Elias A. Immobilization of active bacteriophages on polyhydroxyalkanoate surfaces. ACS Appl. Mater. Interfaces 8(2), 1128-1138 (2016).
48. Khalil RI, Irorere UV, Radecka I et al. Poly-glutamic acid: biodegradable polymer for potential protection of beneficial viruses. Materials 9(1) (2016).
49. Zhang J, Pritchard E, Hu X et al. Stabilization of vaccines and antibiotics in silk and eliminating the cold chain. Proc. Natl Acad. Sci. USA 109(30), 11981-11986 (2012).
50. Sutherland TD, Sriskantha A, Church JS, Strive T, Trueman HE, Kameda T. Stabilization of viruses by encapsulation in silk proteins. ACS Appl. Mater. Interfaces 6(20), 18189-18196 (2014).
51. Semler DD, Goudie AD, Finlay WH, Dennis JJ. Aerosol phage therapy efficacy in burkholderia cepacia complex respiratory infections. Antimicrob. Agents Chemother. 58(7), 4005-4013 (2014).
52. Hansen CR, Pressler T, Koch C, HØiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 4(1), 35-40 (2005).
53. Sahota JS, Smith CM, Radhakrishnan P et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J. Aerosol Med. Pulm. Drug Deliv. 28(5), 353-360 (2015).
54. Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Rel. 70(3), 329-339 (2001).
55. Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of bacteriophages KS4-M and PhiKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 110(1), 106-117 (2011).
56. Vandenheuvel D, Meeus J, Lavigne R, Van den Mooter G. Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. Int. J. Pharm. 472(1-2), 202-205 (2014).
57. Vandenheuvel D, Singh A, Vandersteegen K, Klumpp J, Lavigne R, Van den Mooter G. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. Eur. J. Pharm. Biopharm. 84(3), 578-582 (2013).
58. Dixon DV, Hosseinidoust Z, Tufenkji N. Effects of environmental and clinical interferents on the host capture efficiency of immobilized bacteriophages. Langmuir 30(11), 3184-3190 (2014).
59. Hathaway H, Alves DR, Bean J et al. Poly(N-isopropylacrylamide-co-allylamine) (PNIPAM-co-ALA) nanospheres for the thermally triggered release of Bacteriophage K. Eur. J. Pharm. Biopharm. 96, 437-441 (2015).
60. Starr CR, Engleberg NC. Role of hyaluronidase in subcutaneous spread and growth of group A streptococcus. Infect. Immun.74(1), 40-48 (2006).
61. Bean JE, Alves DR, Laabei M et al. Triggered release of Bacteriophage K from agarose/hyaluronan hydrogel matrixes by Staphylococcus aureus virulence factors. Chem. Mater. 26(24), 7201-7208 (2014).
62. Chen L, Zhao X, Lin Y, Su Z, Wang Q. Dual stimuli-responsive supramolecular hydrogel of bionanoparticles and hyaluronan. Polym. Chem. 5(23), 6754-6760 (2014).
63. Chen Z, Li N, Chen L, Lee J, Gassensmith JJ. Dual functionalized bacteriophage qbeta as a photocaged drug carrier. Small 12(33), 4563-4571 (2016).
64. Schwarz B, Douglas T. Development of virus-like particles for diagnostic and prophylactic biomedical applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7(5), 722-735 (2015).
65. Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum Nature Biotechnol. 24(12), 1508-1511 (2006).
66. Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival of pathogen-directed anti-infectives. J. Med. Microbiol. 62, 1506-1516 (2013).
67. Pohane AA, Jain V. Insights into the regulation of bacteriophage endolysin: multiple means to the same end. Microbiology 161(12), 2269-2276 (2015).
68. Moon BY, Park JY, Robinson DA et al. Mobilization of genomic islands of Staphylococcus aureus by temperate bacteriophage. PLoS ONE 11(3), e0151409 (2016).
69. Ajuebor J, McAuliffe O, O'Mahony J, Ross RP, Hill C, Coffey A. Bacteriophage endolysins and their applications. Sci. Prog. 99(2), 183-199 (2016).
70. Gutierrez D, Ruas-Madiedo P, Martínez B, Rodríguez A, García P. Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS ONE 9(9), e107307 (2014).
71. Singh PK, Donovan DM, Kumar A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob. Agents Chemother. 58(8), 4621-4629 (2014).
72. Fenton M, Keary R, McAuliffe O, Ross RP, O'Mahony J, Coffey A. Bacteriophage-derived peptidase CHAP(K) eliminates and prevents staphylococcal biofilms. Int. J. Microbiol. 2013, 625341 (2013).
73. Shen Y, Koeller T, Kreikemeyer B, Nelson DC. Rapid degradation of Streptococcus pyogenes biofilms by PlyC, a bacteriophage-encoded endolysin. Antimicrob. Agents Chemother. 68(8), 1818-1824 (2013).
74. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418(6900), 884-889 (2002).
75. Lai M-J, Soo P-C, Lin N-T et al. Identification and characterisation of the putative phage-related endolysins through full genome sequence analysis in Acinetobacter baumannii ATCC 17978. Int. J. Antimicrob. Agents 42(2), 141-148 (2013).
76. Lai M-J, Liu C-C, Jiang S-J et al. Antimycobacterial activities of endolysins derived from a mycobacteriophage, BTCU-1. Molecules 20(10), 19277-19290 (2015).
77. Herpers B. Endolysins: redefining antibacterial therapy. Future Microbiol. 10(3), 309-311 (2015).
78. Schuch R, Lee HM, Schneider BC et al. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J. Infect. Dis.209(9), 1469-1478 (2014).
79. Briers Y, Lavigne R. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol. 10(3), 377-390 (2015).
80. Briers Y, Walmagh M, Van Puyenbroeck V et al. Engineered endolysin-based 'artilysins' to combat multidrug-resistant gram-negative pathogens. mBio 5(4), e01379-e02314 (2014).
81. Defraine V, Schuermans J, Grymonprez B et al. Efficacy of Artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob. Agents Chemother. 60(6), 3480-3488 (2016).
82. Gerstmans H, Rodriguez-Rubio L, Lavigne R, Briers Y. From endolysins to Artilysins: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem. Soc. Trans. 44, 123-128 (2016).
83. Rodriguez-Rubio L, Chang WL, Gutierrez D et al. 'Artilysation' of endolysin lambda Sa2lys strongly improves its enzymatic and antibacterial activity against streptococci. Sci. Rep. 6 ( 2016).
84. Filatova LY, Donovan DM, Becker SC et al. Physicochemical characterization of the staphylolytic LysK enzyme in complexes with polycationic polymers as a potent antimicrobial. Biochimie 95(9), 1689-1696 (2013).
85. Fenton M, Casey PG, Hill C et al. The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng. Bugs 1(6), 404-407 (2010).
86. Fenton M, Ross RP, McAuliffe O, O'Mahony J, Coffey A. Characterization of the staphylococcal bacteriophage lysin CHAP(K). J. Appl. Microbiol. 111(4), 1025-1035 (2011).
87. Hathaway H, Ajuebor J, Stephens L et al. Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA). J. Control. Rel. 245, 108-115 (2017).
88. La Ragione RM, Narbad A, Gasson MJ, Woodward MJ. In vivo characterization of Lactobacillus johnsonii FI9785 for use as a defined competitive exclusion agent against bacterial pathogens in poultry. Lett. Appl. Microbiol. 38(3), 197-205 (2004).
89. Gervasi T, Horn N, Wegmann U, Dugo G, Narbad A, Mayer MJ. Expression and delivery of an endolysin to combat Clostridium perfringens. Appl. Microbiol. Biotechnol. 98(6), 2495-2505 (2014).
90. Promise for Antibiotics and Therapeutics for Health Act or the PATH Act S.185. www.congress.gov/bill/114th-congress/senate-bill/185
91. Right to Try Act of 2015 H.R.3012. www.congress.gov/bill/114th-congress/house-bill/3012